Baddi, Himachal Pradesh, has established itself as one of India’s largest pharmaceutical manufacturing hubs. With hundreds of pharmaceutical companies operating in the region, Baddi offers a strategic location, skilled workforce, established vendor networks, and regulatory infrastructure that supports pharmaceutical manufacturing.
For entrepreneurs, pharmaceutical companies, investors, and expansion-focused business groups, acquiring an existing manufacturing facility often provides a faster and more cost-effective route than building a new plant from scratch.
A WHO certified Pharma Plant for sale in Baddi is currently available with an established business, operational manufacturing sections, existing product portfolio, inventory, and annual turnover exceeding ₹25 crore. This opportunity is suitable for companies looking for immediate entry into manufacturing or rapid capacity expansion.
Overview of the Pharma Plant
This is a compact and operational pharmaceutical manufacturing facility located in Baddi, Himachal Pradesh.
Plant Specifications
| Particulars | Details |
|---|---|
| Location | Baddi, Himachal Pradesh |
| Plot Area | 510 Sq. Meter |
| RCC Built-Up Area | Approx. 12,000 Sq. Ft. |
| Additional Platform Area | Approx. 6,000 Sq. Ft. |
| Manufacturing Sections | Tablets, Capsules, Oral Liquids, Dry Syrups |
| WHO Certification | Tablets & Capsules Section |
| Annual Turnover | ₹25 Crore+ |
| Bank Liability | Approx. ₹3 Crore |
| Asking Price | ₹15 Crore |
| Included Assets | Business, Brands, Inventories & Stocks |
The facility offers a ready-to-operate manufacturing setup with established business operations, making it attractive for buyers seeking immediate commercial production capabilities.
Also Read: Pharma Manufacturing Plant for Sale in India – Complete Buyer Guide
Key Features of This WHO Certified Pharma Plant for Sale in Baddi
Running Manufacturing Facility
Unlike greenfield projects that require extensive approvals, construction, validation, and commissioning activities, this unit is already functioning as a pharmaceutical manufacturing business.
Multiple Dosage Form Capabilities
The plant includes manufacturing infrastructure for:
- Tablet manufacturing
- Capsule manufacturing
- Oral liquid production
- Dry syrup manufacturing
This diversified setup enables a buyer to serve multiple therapeutic categories and customer segments.
Existing Business Revenue
One of the strongest advantages is the annual turnover of more than ₹25 crore. The buyer acquires not only manufacturing infrastructure but also an ongoing business operation.
Included Stocks and Inventories
The proposed transaction includes:
- Existing inventories
- Marketed brands
- Finished goods
- Business goodwill
- Manufacturing assets
This significantly reduces the time required to establish commercial operations after acquisition.
Strategic Baddi Location
Baddi remains one of the most preferred pharmaceutical manufacturing destinations in India due to:
- Strong pharma ecosystem
- Vendor availability
- Logistics connectivity
- Skilled manpower
- Regulatory familiarity
- Presence of major pharmaceutical companies
Advantages of Acquiring a Running Pharma Unit in Baddi
Faster Market Entry
Setting up a new pharmaceutical manufacturing plant may take 18–36 months depending on approvals, construction, equipment procurement, validation, and licensing.
Acquiring a running unit can dramatically shorten the timeline.
Reduced Capital Risk
A functioning business provides:
- Existing customer base
- Manufacturing infrastructure
- Trained workforce
- Established operational systems
This lowers startup-related uncertainties.
Revenue from Day One
The plant’s established turnover provides immediate commercial activity, unlike a new project that may require years to achieve similar revenue levels.
Expansion Opportunity
The existing RCC shed and additional platform area offer future possibilities for:
- Capacity enhancement
- Additional dosage forms
- Contract manufacturing
- Third-party manufacturing services
Established Market Presence
Acquiring a business with existing brands can provide a valuable market advantage compared with launching completely new products.
Also read: Pharmaceutical Manufacturing Facility in Baddi-Fully Functional
Regulatory and Compliance Relevance
Regulatory compliance is one of the most important considerations in pharmaceutical acquisitions.
WHO Certification
The tablet and capsule manufacturing sections are WHO certified, which can support:
- Domestic institutional business
- Government tenders
- Export-oriented opportunities (subject to country-specific requirements)
- Enhanced customer confidence
Manufacturing Compliance
Potential buyers should conduct comprehensive due diligence on:
- Manufacturing licenses
- Product permissions
- GMP documentation
- Validation records
- Equipment qualification status
- Annual product reviews
- Stability studies
- Regulatory inspection history
A structured due diligence process helps ensure smooth ownership transition and regulatory continuity.
Business Opportunity for Investors and Pharma Entrepreneurs
Ideal Buyers
This opportunity may be suitable for:
Pharmaceutical Companies
Companies looking to expand manufacturing capacity without developing a greenfield facility.
PCD Pharma Companies
Marketing-focused companies seeking backward integration into manufacturing.
Contract Manufacturers
Organizations interested in increasing production capabilities.
Investors
Investors looking to acquire a revenue-generating pharmaceutical asset.
Export-Oriented Businesses
Businesses planning to develop regulated and semi-regulated market opportunities.
Why Baddi Continues to Attract Pharma Investments
Baddi has become synonymous with pharmaceutical manufacturing in India. The region hosts numerous manufacturing facilities across:
- Tablets
- Capsules
- Injectables
- Liquids
- Dry syrups
- Nutraceuticals
- Ayurvedic products
Key advantages include:
- Mature pharmaceutical ecosystem
- Availability of technical talent
- Supplier network accessibility
- Strong logistics infrastructure
- Proven regulatory environment
As pharmaceutical demand continues to grow in India and export markets, operational facilities in established clusters remain highly sought-after assets.
Why This Opportunity Matters for Pharma Industry Buyers
Acquiring a running compact size pharma unit in Baddi offers a combination of manufacturing capability, established business operations, existing product portfolio, and market presence.
Instead of investing significant time and capital in land acquisition, construction, equipment procurement, and regulatory approvals, buyers can focus on scaling operations and growing revenue.
For organizations seeking a WHO certified Pharma Plant for sale in Baddi with diversified dosage forms and existing turnover, this facility presents a practical acquisition opportunity.
Conclusion
The availability of a WHO certified Pharma Plant for sale in Baddi with tablet, capsule, oral liquid, and dry syrup manufacturing capabilities represents a valuable opportunity for pharmaceutical entrepreneurs, investors, contract manufacturers, and expansion-focused companies.
With an annual turnover exceeding ₹25 crore, existing inventories, established brands, and operational manufacturing infrastructure, the facility offers immediate business potential along with future growth opportunities.
Interested in Acquiring This Pharma Plant?
Laafon.com specializes in connecting serious buyers and sellers of pharmaceutical manufacturing facilities across India.
Contact our team today for detailed project information, financial discussions, plant visit scheduling, and acquisition support.
Frequently Asked Questions (FAQs)
-
What is the asking price of this WHO certified Pharma Plant for sale in Baddi?
The expected transaction value is approximately ₹13–15 crore, including business operations, inventories, stocks, and brands.
-
What manufacturing sections are available in the plant?
The facility includes tablet, capsule, oral liquid, and dry syrup manufacturing sections.
-
Is the plant currently operational?
Yes. The facility is a running pharmaceutical manufacturing unit with annual turnover exceeding ₹25 crore.
-
Does the plant have WHO certification?
Yes. The tablet and capsule manufacturing sections are WHO certified.
-
What is the built-up area of the facility?
The unit includes approximately 12,000 sq. ft. RCC covered area and an additional 6,000 sq. ft. platform area.
-
Who should consider purchasing this pharma unit?
Pharmaceutical companies, PCD businesses, contract manufacturers, investors, and healthcare entrepreneurs can benefit from this acquisition opportunity.
-
Why is Baddi considered a preferred pharma manufacturing location?
Baddi offers a strong pharmaceutical ecosystem, skilled manpower, vendor availability, logistics advantages, and established regulatory infrastructure.
